SynFlora is working on bioengineering a skincare revolution

Date:

Share post:


Biotech startup SynFlora brought an enticing pitch for a new type of skin treatment technology to 4YFN at the MWC tradeshow in Barcelona this week. The Spanish startup, whose three co-founders all have PhDs, is working to improve understanding of the skin’s microbiome and engineer skin microbes with the goal of enabling more targeted and novel therapeutics.

The basic idea is to deliver treatments in a deeper way than topically applied creams, such as is the case with current-gen ‘active’ skincare products — but also to design and engineer a wider range of treatments by using biotech methods to harness bacteria to deliver targeted therapeutics.

“We are creating a base of a new skin product which is not anymore just molecules, which can’t enter the skin because they’re topically applied — it’s really like a molecular machine,” says co-founder and CEO Nastassia Knōdlseder. “A bacteria which can move inside the hair follicle, like deep inside the skin, and produce new [effects].”

The team’s early research “proof of concept” work is focused on acne — and it’s recently published a paper on its experimental treatment delivery approach in the journal Nature Biotechnology (on a test of a “sebum modulator” in an engineered skin microbe in mice) — but they envisage the approach being applied to tackle a much wider range of issues. Including things that range well beyond what we might consider skincare.

Potential use-cases they mention could include mosquito repellant or fat loss (a cream for making cellulite disappear anyone?), per Knōdlseder, or even vaccines and anti-inflammatory treatments.

“We have the potential triggering the immune system or creating vaccines against melanoma, for example,” she suggests. “We have the possibility of the production of anti-inflammatory molecules.”

“We see this really like as a platform,” she adds, confirming the team has patents for different indictions of the technology and for the platform itself. “We really don’t want to limit to one use-case.”

SynFlora is still at an early stage — they’re in the process of raising a seed round, per Knōdlseder — and will obviously need to satisfy regulators of the safety and efficacy of their novel bioengineered mechanism for delivering therapeutics deeper into the dermis before the tech will be able to reach consumers.

But the co-founders suggest they could be between one to three years away from their novel system powering a new generation of skin-delivered therapeutics.



Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

Your Android phone could have stalkerware — here’s how to remove it

Consumer-grade spyware apps that covertly and continually monitor your private messages, photos, phone calls and real-time location...

Harvard’s startup whisperer, Peter Gladstone, reveals secrets to validating consumer demand at TechCrunch Early Stage

Validating consumer demand is a crucial step for any startup, and TechCrunch Early Stage is offering a...

Post News, the a16z-funded Twitter alternative, is shutting down

Post News, a microblogging site that emerged in the days after Elon Musk’s Twitter acquisition, is shutting...

Wall Street doesn’t seem too keen on a potential Salesforce-Informatica pairing

When a significant rumor emerged last weekend that Salesforce was interested in buying Informatica, a legacy data...

Equities platform Midas raises $45M Series A as fintech retains its sparkle in Turkey

Midas, a fintech startup that allows people in Turkey to invest in U.S. and Turkish equities, says...

TechCrunch Minute: Meta’s new Llama 3 models give open-source AI a boost

New AI models from Meta are making waves in technology circles. The two new models, part of...

Tesla’s newsy week, and is fintech having a moment?

It’s been more than a minute since Tesla went public, but the EV company was inescapable on...

Webflow acquires Intellimize to add AI-powered webpage personalization

Webflow, a web design and hosting platform that’s raised over $330 million at a $4 billion valuation,...